|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:1996
gptkb:FDA
|
|
gptkbp:average_temperature
|
room temperature
|
|
gptkbp:category
|
gptkb:unknown
gptkb:C
|
|
gptkbp:class
|
alpha-2 adrenergic agonist
|
|
gptkbp:clinical_trial
|
Phase IV
|
|
gptkbp:clinical_use
|
long-term management of glaucoma
ocular hypertension treatment
|
|
gptkbp:community_service
|
not established
|
|
gptkbp:contraindication
|
hypersensitivity to brimonidine
|
|
gptkbp:counseling_services
|
store at room temperature
discard after 28 days of opening
avoid contact with soft contact lenses
|
|
gptkbp:dosage_form
|
gptkb:Software_Solutions
1 drop in affected eye(s) twice a day
|
|
gptkbp:drug_interactions
|
antidepressants
MAO inhibitors
sedatives
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:cream
0.1% solution
0.15% solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Alphagan
|
|
gptkbp:indication
|
gptkb:ocular_hypertension
|
|
gptkbp:ingredients
|
gptkb:brimonidine
|
|
gptkbp:lifespan
|
2-4 hours
|
|
gptkbp:manufacturer
|
gptkb:Allergan
|
|
gptkbp:mechanism_of_action
|
reduces aqueous humor production
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:pharmacokinetics
|
peak plasma concentration in 2 hours
|
|
gptkbp:provides_guidance_on
|
recommended as first-line therapy
used in combination therapy
|
|
gptkbp:requires
|
prescription only
|
|
gptkbp:route_of_administration
|
ocular
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
dry mouth
allergic conjunctivitis
visual disturbances
eye redness
eyelid retraction
|
|
gptkbp:trade
|
gptkb:Alphagan_P
|
|
gptkbp:used_for
|
gptkb:Ophthalmology
|
|
gptkbp:bfsParent
|
gptkb:Valeant_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
6
|